(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 13.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Mannkind's revenue in 2025 is $301,736,000.On average, 10 Wall Street analysts forecast MNKD's revenue for 2025 to be $100,550,713,663, with the lowest MNKD revenue forecast at $93,904,811,927, and the highest MNKD revenue forecast at $107,509,580,301. On average, 10 Wall Street analysts forecast MNKD's revenue for 2026 to be $120,012,834,952, with the lowest MNKD revenue forecast at $103,167,959,360, and the highest MNKD revenue forecast at $151,097,613,571.
In 2027, MNKD is forecast to generate $134,357,059,613 in revenue, with the lowest revenue forecast at $114,563,563,722 and the highest revenue forecast at $180,737,230,732.